Zobrazeno 1 - 10
of 1 182
pro vyhledávání: '"iraes"'
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-9 (2024)
Abstract Purpose Immune checkpoint inhibitors (ICIs) have improved lung cancer treatment but are associated with immune-related adverse events (irAEs). This study analyzes the relationship between irAEs and treatment effectiveness in advanced non-sma
Externí odkaz:
https://doaj.org/article/24f89ff893744ad6999c19926809fba4
Autor:
Jian Zhang, Aiqin Gao, Shuyun Wang, Yanxin Sun, Jiake Wu, Dahai Wang, Yihui Ge, Juan Li, Haifeng Sun, Qinglei Cheng, Yuping Sun
Publikováno v:
Respiratory Research, Vol 25, Iss 1, Pp 1-8 (2024)
Abstract Background Patients receiving PD-(L)1 inhibitors frequently encounter unusual side effects known as immune-related adverse events (irAEs). However, the correlation of irAEs development with clinical response in small cell lung cancer (SCLC)
Externí odkaz:
https://doaj.org/article/81edf98278c9466d9563b891d6a4d6fb
Publikováno v:
BMC Ophthalmology, Vol 24, Iss 1, Pp 1-5 (2024)
Abstract Background Several immune checkpoint inhibitors (ICIs) have been linked to the occurrence of Vogt-Koyanagi-Harada disease (VKHD)-like uveitis. Among the ICIs, there has been no report of immune-related adverse events (irAEs) caused by a new
Externí odkaz:
https://doaj.org/article/7b3510b0118443cda7c969e77b208cfb
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThe discovery and development of immune checkpoint inhibitors (ICIs) have resulted in their application as a novel therapeutic strategy for patients with small-cell lung cancer (SCLC). However, a comprehensive analysis of the potential adve
Externí odkaz:
https://doaj.org/article/5ae4c212c0f64944b6212f9b26ad5e1c
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundUnderstanding the risk relationship between statin use and immune-related adverse events (irAEs) in patients undergoing immune checkpoint inhibitors (ICIs) therapy is crucial for optimizing oncological management.ObjectiveThis study aimed t
Externí odkaz:
https://doaj.org/article/b137d2ea6435474c81af64f6c1136dae
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
PurposeTo assess the potential added value of the lung immune prognostic index (LIPI) in patients with small cell lung cancer (SCLC), treated with programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) inhibitors, who lived in the Chinese alpine
Externí odkaz:
https://doaj.org/article/bbe233e33f694ba3b1f2c43e1eb8026a
Autor:
Ryo Takada, Miki Fujiwara, Masatoshi Maki, Naoyuki Nomura, Shintaro Kono, Akira Fujita, Hiroshi Masumoto, Yoko Takahashi, Yasuhisa Hasegawa, Koji Tamura
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract Background Ipilimumab (Ipi) plus nivolumab (Nivo) is the recommended first-line treatment for renal cell carcinoma (RCC). This report describes a case where pancreatic metastases disappeared after only two courses of Ipi + Nivo therapy. The
Externí odkaz:
https://doaj.org/article/520b8f63e6f345f1bc3b0b880b5ef58a
Autor:
Baike Liu, Zheran Liu, Tianxiang Jiang, Xiangshuai Gu, Xiaonan Yin, Zhaolun Cai, Xiaoqiao Zou, Lei Dai, Bo Zhang
Publikováno v:
European Journal of Medical Research, Vol 29, Iss 1, Pp 1-16 (2024)
Abstract Background In cancer patients receiving immune checkpoint inhibitors (ICIs), there is emerging evidence suggesting a correlation between gut microbiota and immune-related adverse events (irAEs). However, the exact roles of gut microbiota and
Externí odkaz:
https://doaj.org/article/c053d50499fb49ce80e7e80ed42de623
Autor:
Shuming Chen, Tracee L. McMiller, Abha Soni, Farah Succaria, John-William Sidhom, Laura C. Cappelli, Livia A. Casciola-Rosen, Isaac R. Morales, Preethi Sankaran, Alan E. Berger, Julie Stein Deutsch, Qingfeng C. Zhu, Robert A. Anders, Jody E. Hooper, Drew M. Pardoll, Evan J. Lipson, Janis M. Taube, Suzanne L. Topalian
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Tumor regression following immune checkpoint blockade (ICB) is often associated with immune-related adverse events (irAEs), marked by inflammation in non-cancerous tissues. This study was undertaken to investigate the functional r
Externí odkaz:
https://doaj.org/article/44edc95deb6444eabbd3e50a4991237d
Autor:
Yunyi Du, Ying Zhang, Wenqi Zhao, Yuexiang Zhang, Fei Su, Xiaoling Zhang, Weiling Li, Wenqing Hu, Yongai Li, Jun Zhao
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Immune-related adverse events (irAEs) impact outcomes, with most research focusing on early prediction (baseline data), rather than near-term prediction (one cycle before the occurrence of irAEs and the current cycle). We aimed to explore the near-te
Externí odkaz:
https://doaj.org/article/6ddbeb11c972409dae8f6bd9bc4970d2